Cargando…
Programmed Death 1 (PD-1) Expression in Relapsing and Remitting Hodgkin Lymphoma as Prognostic Factor
BACKGROUND: Programmed death ligand 1 (PD-L1) plays critical role in PD-1-dependent immunity suppress. Abnormal PD-L1 expression has shown to be directly related to poor prognosis and drug resistance in cancer patients. Hence, we aimed to evaluate PD-L1 expression in relapsing and remitting Hodgkin...
Autores principales: | Bouzari, Behnaz, Basi, Ali, Dadkhah, Shadi, Panahi, Mahshid, Mohammadi, Soha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685244/ https://www.ncbi.nlm.nih.gov/pubmed/37642071 http://dx.doi.org/10.31557/APJCP.2023.24.8.2829 |
Ejemplares similares
-
PB2435: ALLOGENEIC STEM CELL TRANSPLANTATION OUTCOMES IN HODGKIN LYMPHOMA: A PROGNOSTIC STUDY OF 30 PATIENTS WITH RELAPSED AND REFRACTORY HODGKIN LYMPHOMA
por: Zamani, Shayan, et al.
Publicado: (2023) -
Effectiveness of chemotherapy after anti‐PD‐1 blockade failure for relapsed and refractory Hodgkin lymphoma
por: Casadei, Beatrice, et al.
Publicado: (2020) -
Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation
por: Manson, Guillaume, et al.
Publicado: (2020) -
High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma
por: Chen, Xi, et al.
Publicado: (2022) -
Long‐term efficacy and safety of programmed death‐1 (PD‐1) antibody alone in relapsed/refractory human immunodeficiency virus‐associated Hodgkin lymphoma
por: Wang, Chaoyu, et al.
Publicado: (2022)